Literature DB >> 19968402

Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants.

Ajna Hamidovic1, Andrea Dlugos, Andrew Skol, Abraham A Palmer, Harriet de Wit.   

Abstract

The dopamine D2 receptor (DRD2) appears to be involved in impulsive behaviors, and particularly in behavioral inhibition. We sought to determine whether inhibition and impulsivity were related to genetic polymorphisms in the DRD2 gene (DRD2) in healthy volunteers (N = 93). Participants received placebo or d-amphetamine in random order. They performed the stop task, measuring behavioral inhibition, and rated their mood states on each session. They also completed the Zuckerman-Kuhlman Personality Questionnaire, including an Impulsivity subscale. We investigated the association between 12 single nucleotide polymorphisms (SNPs) and haplotypes in DRD2 and stop task performance in the nondrug (i.e., placebo) session and on the personality measure of impulsivity. We secondarily evaluated the DRD2 SNPs in relation to response to d-amphetamine on stop task performance and mood ratings. Mood was not related to genotypes in either the drug free condition or in response to drug. However, 2 SNPs, rs4648317 and rs12364283, and a haplotype block consisting of those SNPs, were associated with better performance on the stop task in the drug free condition and lower scores on the Impulsivity subscale. We also found that rs12364283 was associated with effects of d-amphetamine on stop task performance: d-amphetamine decreased stop reaction time (RT) in the A/A group but increased stop RT in the combined A/G + G/G genotype. Of the SNPs we evaluated, rs12364283, which has been associated with DRD2 expression, was the most significantly associated with inhibition and impulsivity. The significant relationship between DRD2 genotype and both behavioral inhibition and impulsivity suggests a possible common genetic influence on behavioral and self-report measures of impulsivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19968402      PMCID: PMC2879583          DOI: 10.1037/a0017840

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  53 in total

1.  Inference of population structure using multilocus genotype data.

Authors:  J K Pritchard; M Stephens; P Donnelly
Journal:  Genetics       Date:  2000-06       Impact factor: 4.562

2.  Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals.

Authors:  Dmitri V Zaykin; Peter H Westfall; S Stanley Young; Maha A Karnoub; Michael J Wagner; Margaret G Ehm
Journal:  Hum Hered       Date:  2002       Impact factor: 0.444

3.  The structure of haplotype blocks in the human genome.

Authors:  Stacey B Gabriel; Stephen F Schaffner; Huy Nguyen; Jamie M Moore; Jessica Roy; Brendan Blumenstiel; John Higgins; Matthew DeFelice; Amy Lochner; Maura Faggart; Shau Neen Liu-Cordero; Charles Rotimi; Adebowale Adeyemo; Richard Cooper; Ryk Ward; Eric S Lander; Mark J Daly; David Altshuler
Journal:  Science       Date:  2002-05-23       Impact factor: 47.728

4.  Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals.

Authors:  N D Volkow; R C Gur; G J Wang; J S Fowler; P J Moberg; Y S Ding; R Hitzemann; G Smith; J Logan
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

5.  Changes in activities of dopamine and serotonin systems in the frontal cortex underlie poor choice accuracy and impulsivity of rats in an attention task.

Authors:  T Puumala; J Sirviö
Journal:  Neuroscience       Date:  1998-03       Impact factor: 3.590

6.  Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans.

Authors:  H de Wit; J Crean; J B Richards
Journal:  Behav Neurosci       Date:  2000-08       Impact factor: 1.912

Review 7.  The dynamic approach to neurodevelopmental psychiatric disorders: use of fMRI combined with neuropsychology to elucidate the dynamics of psychiatric disorders, exemplified in ADHD and schizophrenia.

Authors:  Katya Rubia
Journal:  Behav Brain Res       Date:  2002-03-10       Impact factor: 3.332

8.  Allelic association between D2 but not D1 dopamine receptor gene and alcoholism in Finland.

Authors:  J Hietala; T Pohjalainen; U Heikkilä-Kallio; C West; M Salaspuro; E Syvälahti
Journal:  Psychiatr Genet       Date:  1997       Impact factor: 2.458

9.  Using MRI to examine brain-behavior relationships in males with attention deficit disorder with hyperactivity.

Authors:  M Semrud-Clikeman; R J Steingard; P Filipek; J Biederman; K Bekken; P F Renshaw
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-04       Impact factor: 8.829

10.  Impulsive choice induced in rats by lesions of the nucleus accumbens core.

Authors:  R N Cardinal; D R Pennicott; C L Sugathapala; T W Robbins; B J Everitt
Journal:  Science       Date:  2001-05-24       Impact factor: 47.728

View more
  50 in total

1.  Pregabalin- and topiramate-mediated regulation of cognitive and motor impulsivity in DBA/2 mice.

Authors:  Francisco Navarrete; José M Pérez-Ortiz; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Striatal dopamine D₂/D₃ receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans.

Authors:  Dara G Ghahremani; Buyean Lee; Chelsea L Robertson; Golnaz Tabibnia; Andrew T Morgan; Natalie De Shetler; Amira K Brown; John R Monterosso; Adam R Aron; Mark A Mandelkern; Russell A Poldrack; Edythe D London
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

Review 3.  Introduction to behavioral addictions.

Authors:  Jon E Grant; Marc N Potenza; Aviv Weinstein; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2010-09       Impact factor: 3.829

4.  Nucleus accumbens responses differentiate execution and restraint in reward-directed behavior.

Authors:  Jamie D Roitman; Amy L Loriaux
Journal:  J Neurophysiol       Date:  2013-10-30       Impact factor: 2.714

5.  Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum.

Authors:  Robert C Lorenz; Tobias Gleich; Ralph Buchert; Florian Schlagenhauf; Simone Kühn; Jürgen Gallinat
Journal:  Hum Brain Mapp       Date:  2015-07-14       Impact factor: 5.038

Review 6.  Prefrontal cortex executive processes affected by stress in health and disease.

Authors:  Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-07-06       Impact factor: 5.067

7.  DRD2 polymorphisms modulate reward and emotion processing, dopamine neurotransmission and openness to experience.

Authors:  Marta Peciña; Brian J Mickey; Tiffany Love; Heng Wang; Scott A Langenecker; Colin Hodgkinson; Pei-Hong Shen; Sandra Villafuerte; David Hsu; Sara L Weisenbach; Christian S Stohler; David Goldman; Jon-Kar Zubieta
Journal:  Cortex       Date:  2012-02-14       Impact factor: 4.027

Review 8.  A review of pharmacogenetic studies of substance-related disorders.

Authors:  Jermaine D Jones; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

9.  Affiliation with substance-using peers: Examining gene-environment correlations among parent monitoring, polygenic risk, and children's impulsivity.

Authors:  Kit K Elam; Laurie Chassin; Kathryn Lemery-Chalfant; Danielle Pandika; Frances L Wang; Kaitlin Bountress; Danielle Dick; Arpana Agrawal
Journal:  Dev Psychobiol       Date:  2017-05-31       Impact factor: 3.038

10.  Effects of smoking abstinence on smoking-reinforced responding, withdrawal, and cognition in adults with and without attention deficit hyperactivity disorder.

Authors:  Scott H Kollins; Joseph S English; Michelle E Roley; Benjamin O'Brien; Justin Blair; Scott D Lane; F Joseph McClernon
Journal:  Psychopharmacology (Berl)       Date:  2012-12-18       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.